Skip to main navigation Skip to search Skip to main content

Evaluating the efficacy and mechanism of metformin targets on reducing Alzheimer’s disease risk in the general population: a Mendelian randomisation study

  • Jie Zheng
  • , Min Xu
  • , Venexia Walker
  • , Jinqiu Yuan
  • , Roxanna Korologou-Linden
  • , Jamie Robinson
  • , Peiyuan Huang
  • , Stephen Burgess
  • , Shiu Lun Au Yeung
  • , Shan Luo
  • , Michael V. Holmes
  • , George Davey Smith
  • , Guang Ning
  • , Weiqing Wang
  • , Tom R. Gaunt
  • , Yufang Bi

Research output: Contribution to journal › Article › peer-review

82 Citations (Scopus)

Abstract

Aims/hypothesis: Metformin use has been associated with reduced incidence of dementia in diabetic individuals in observational studies. However, the causality between the two in the general population is unclear. This study uses Mendelian randomisation (MR) to investigate the causal effect of metformin targets on Alzheimer’s disease and potential causal mechanisms in the brain linking the two. Methods: Genetic proxies for the effects of metformin drug targets were identified as variants in the gene for the corresponding target that associated with HbA1c level (N=344,182) and expression level of the corresponding gene (N≤31,684). The cognitive outcomes were derived from genome-wide association studies comprising 527,138 middle-aged Europeans, including 71,880 with Alzheimer’s disease or Alzheimer’s disease-by-proxy. MR estimates representing lifelong metformin use on Alzheimer’s disease and cognitive function in the general population were generated. Effect of expression level of 22 metformin-related genes in brain cortex (N=6601 donors) on Alzheimer’s disease was further estimated. Results: Genetically proxied metformin use, equivalent to a 6.75 mmol/mol (1.09%) reduction on HbA1c, was associated with 4% lower odds of Alzheimer’s disease (OR 0.96 [95% CI 0.95, 0.98], p=1.06×10−4) in non-diabetic individuals. One metformin target, mitochondrial complex 1 (MCI), showed a robust effect on Alzheimer’s disease (OR 0.88, p=4.73×10−4) that was independent of AMP-activated protein kinase. MR of expression in brain cortex tissue showed that decreased MCI-related gene (NDUFA2) expression was associated with lower Alzheimer’s disease risk (OR 0.95, p=4.64×10−4) and favourable cognitive function. Conclusions/interpretation: Metformin use may cause reduced Alzheimer’s disease risk in the general population. Mitochondrial function and the NDUFA2 gene are plausible mechanisms of action in dementia protection. Graphical abstract: [Figure not available: see fulltext.]

Original languageEnglish
Pages (from-to)1664-1675
Number of pages12
JournalDiabetologia
Volume65
Issue number10
DOIs
Publication statusPublished - Oct 2022
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Alzheimer’s disease
  • Brain expression
  • Cognitive function
  • Dementia
  • Mendelian randomisation
  • Metformin targets
  • Mitochondrial function

Fingerprint

Dive into the research topics of 'Evaluating the efficacy and mechanism of metformin targets on reducing Alzheimer’s disease risk in the general population: a Mendelian randomisation study'. Together they form a unique fingerprint.

Cite this